FORUM REVIEW ARTICLE

Harnessing Proteasome Dynamics and Allostery in Drug Design

Maria Gaczynska and Pawel A. Osmulski

Abstract

Significance: The proteasome is the essential protease that is responsible for regulated cleavage of the bulk of intracellular proteins. Its central role in cellular physiology has been exploited in therapies against aggressive cancers where proteasome-specific competitive inhibitors that block proteasome active centers are very effectively used. However, drugs regulating this essential protease are likely to have broader clinical usefulness. The non-catalytic sites of the proteasome emerge as an attractive alternative target in search of highly specific and diverse proteasome regulators. **Recent Advances:** Crystallographic models of the proteasome leave the false impression of fixed structures with minimal molecular dynamics lacking long-distance allosteric signaling. However, accumulating biochemical and structural observations strongly support the notion that the proteasome is regulated by precise allosteric interactions arising from protein dynamics, encouraging the active search for allosteric regulators. Here, we discuss properties of several promising compounds that affect substrate gating and processing in antechambers, and interactions of the catalytic core with regulatory proteins. **Critical Issues:** Given the structural complexity of proteasome assemblies, it is a painstaking process to better understand their allosteric regulation and molecular dynamics. Here, we discuss the challenges and achievements in this field. We place special emphasis on the role of atomic force microscopy imaging in probing the allostery and dynamics of the proteasome, and in dissecting the mechanisms involving small-molecule allosteric regulators. **Future Directions:** New small-molecule allosteric regulators may become a next generation of drugs targeting the proteasome, which is critical to the development of new therapies in cancers and other diseases. *Antioxid. Redox Signal.* 21, 2286–2301.

Introduction

NEARLY 50 YEARS has passed since the first model of protein allostery, the Monod–Wyman–Changeux, was introduced (89). This model, and the alternative or refinement models which followed, postulated that a ligand binding at an allosteric site induces a conformational change at a distant site. At first, the concept was based on the elegant example of cooperative binding of oxygen by the hemoglobin tetramer; it evolved through the years and included conformational diversity and multiple pathways where structural signals can be transferred over large distances to change the properties of the subject protein. Instead of ligand-induced switching between two exclusive conformational forms, there are

population shifts between multiple conformers that co-exist in the ensemble of conformational states (25). Rather than signaling between subunits in oligomeric assemblies, all globular dynamic proteins are considered allosteric (56). In addition, instead of allostery involved in only highly specific routes of regulation, the “at a distance signaling” is perceived to have a broad significance at the molecular and cellular levels, from underlying biological catalysis to communicating environmental signals (25, 46). The allosteric perturbation may originate in covalent or noncovalent events, in binding an ion or a small or a large molecule, in mutations, or even in light absorption (95, 122, 127). It, therefore, seems obvious that allosteric ligands should be attractive as drugs. First, the enzyme likely has more allosteric sites that are

Department of Molecular Medicine, Institute of Biotechnology, University of Texas Health Science Center at San Antonio, San Antonio, Texas.

suitable for targeting than orthosteric sites, with the latter being directly responsible for catalytic activity. Effects of allosteric drugs could be much more versatile than blocking the orthosteric site and specific inactivation of a target protein. Moreover, allosteric sites are usually more unique than orthosteric sites, which are shared by all enzymes in a family; therefore, allosteric drugs should be exceptionally specific in their actions (95). Allosteric sites are also under less evolutionary pressure than orthosteric sites, and allosteric ligands are less likely to induce protective or adaptive reactions resulting in poor response or resistance to the drug. It is also worth remembering that using drugs based on classical competitive orthosteric inhibition, similar to most of the current targeted therapeutics, may likely lead to the accumulation of the unprocessed substrate to a point that it may outcompete the inhibitor, creating an anti-inhibition feedback loop. In this regard, an uncompetitive mechanism is the most desired, as the inhibitor binding to the already assembled enzyme–substrate complex cannot be overcome by either the overproduction of enzyme or the accumulation of substrate. Despite these advantages, allosteric drugs are under-utilized and are gaining popularity relatively slowly. Part of the problem is an inadequate understanding of the intricate allosteric networks at the molecular and cellular levels. The goal of this review is to discuss the potential opportunities for the use of allosteric ligands to control the actions of an attractive drug target, namely, the proteasome—an essential human protease—and the regulator of intracellular physiology.

The Proteasome: An Intracellular Protein Processing Plant

The proteasome is an essential protease of the ubiquitin-proteasome pathway (UPP) that degrades the bulk of intracellular proteins, including vital regulatory factors and damaged polypeptides (21). Twenty years have passed since the physiological significance of the UPP, and, in particular, since the proteasome first started emerging (40, 104, 105, 112). As the broad involvement of the proteasome in the regulation of cell cycle, apoptosis, antigen processing, or stress response became evident, disrupting this ubiquitous protease function with specific inhibitors seemed to provide a viable pro-apoptotic or anti-inflammatory strategy. Indeed, proteasome inhibition has proved to be a very effective anti-cancer treatment (see Soriano *et al.*, this Forum). Up to now, two small-molecule drugs, bortezomib (VelcadeTM) and PR-171 (KyprolisTM), are FDA approved to treat blood cancers, and several other similar-acting compounds are in human trials (1, 26, 66). All these drugs specifically target orthosteric sites of the proteasome. Before we can begin to discuss the usefulness of allosteric sites, we need to briefly present the structure of the proteasome, revealed by X-ray crystallography (50, 63, 85, 130) and cryo-electron microscopy (cryoEM) combined with molecular modeling studies (30, 79, 80).

The proteasome is a complex and diverse enzymatic factory that is often compared with a molecular organelle (see Soriano *et al.*, this Forum). The name “proteasome” encompasses several assemblies with a common catalytic core and additional regulatory proteins that are capable of attaching to the core and modulating its function (49). All “greater proteasome” assemblies contain a tube-shaped 20S (S denotes Svedberg sedimentation units) catalytic core of

700 kDa (core particle [CP]) that is constructed from four hetero heptameric rings of pseudo seven-fold symmetry. The two α and two β rings are stacked in an α – β – β – α manner and are built from tightly arranged homologous subunits, respectively, designated α 1– α 7 and β 1– β 7. The external α rings form the α face: a nearly flat surface that binds additional protein modules regulating the proteasome function (Fig. 1A). The center of the α ring is occupied by “the gate,” which provides passage to the central channel leading to the antechamber and then into the spacious catalytic chamber, formed inside β -rings. The gate is tightly closed in the canonical crystal structures of wild-type Eukaryotic 20S. Substrate access to the catalytic chamber is enabled when the gate is opened (50, 63, 130). In humans, as in other Eukaryotes, there are three pairs of active centers that cleave peptide bonds on the carboxyl side of hydrophobic (chymotrypsin-like peptidase activity [ChT-L]), basic (trypsin-like activity [T-L]), and acidic (post-glutamyl peptide hydrolyzing activity [PGPH]; caspase-like) amino acids. The ChT-L site can additionally process branched amino acids (branched amino-acid processing activity), and the PGPH site is capable of also cleaving after small neutral amino acids (small neutral amino-acid processing activity) (97). The ChT-L, T-L and PGPH activities are provided by active centers that are harbored by β 5, β 2, and β 1 subunits, respectively (5, 27). All active sites are of the rare N-terminal threonine type (29, 121). The constitutive, or “housekeeping” β 5, β 2, and β 1 subunits of higher vertebrates can be replaced by interferon- γ inducible β 5i, β 2i, and β 1i “immunosubunits.” Here, the active centers are modified to accommodate more efficient production of peptides serving as antigens for major histocompatibility complex class I antigen processing (40, 63, 113). In addition to housekeeping and immunoproteasomes, there are thymus-specific “thymo-proteasomes” that feature a specific β 5t subunit accompanied by β 2i and β 1i. This plays a role in the positive selection and maturation of CD8⁺ T cells (129).

The 20S core alone is capable of degrading peptides, denatured proteins, and proteins with unorganized domains (84, 94). The activity of the core can be modulated by the attachment of additional proteins or protein complexes to one or both α rings. The two α faces may be occupied by the same or distinct modules (49, 59). The proteasome inhibitor PI31 is perhaps the smallest attachment, of molecular weight, comparable to the core subunits (20, 87). PI31 most likely regulates protein–protein interactions within the “greater proteasome” (7, 18, 69). Another single protein module is proteasome activator PA200 (Blm10), a large, 200 kDa protein of HEAT repeat-driven circular structure, that is predominantly found in mixed assemblies PA200–20S–19S. This assembly is primarily involved in DNA repair and maintaining mitochondrial function (Fig. 1B) (115, 118, 131). Next in the line of special attachments to the 20S core are 11S PAs/regulators with 28 kDa subunits (PA28/regulator [REG]; Fig. 1C) (32, 134). They come in two homologous forms, as either heptamers built from α and β subunits or from γ subunits (110). The interferon- γ inducible PA28 $\alpha\beta$ facilitates the production of antigenic peptides and the degradation of oxidatively damaged proteins (47, 107). The PA28 γ is often found in the nucleus and assists in the degradation of specific substrates (110). Direct structural evidence and biochemical data demonstrate that the activators open or disorganize the

FIG. 1. The basic types of the “proteasome” assemblies. (A) The catalytic core proteasome, side and top views, based on the yeast 1RYP crystal structure (50). The position of $\alpha 1$ subunit in the α ring is marked. Looking from the top of α face down the molecule, the subunits, all about 20–30 kDa, are arranged from 1 to 7 counterclockwise (proximal α ring)—clockwise (proximal β ring)—counterclockwise (distal β ring)—clockwise (distal α ring). The 1RYP-based models of 20S are used in all subsequent figures. (B) The PA200 activator in complex with the core particle forming PA200-20S-PA200 assembly; based on the crystal structure 3L5Q (115). (C) The “activated proteasome” assembly 11S-20S-11S, based on the crystal structure 1FNT, of the 20S core in complex with PA26 activator, a homolog of PA28/REG (134). (D) The 26S assembly (19S-20S-19S) based on the EM and molecular modeling. The cartoon renderings of topography of regulatory modules were constructed from the crystal structures or EM/modeling, as indicated (79). Reproduced by permission from Osmulski and Gaczynska (102) modified. ER, electron microscopy; PA, proteasome activator; REG, regulator; S, Svedberg sedimentation unit.

gate, thus enabling the substrates to enter and the cleaved products to leave the catalytic chamber (110, 115, 134). While not diminishing the role of the above modules, the 19S cap, or regulatory particle (RP) is the most broadly involved in cellular physiology. It is also the largest and most complex of the core-binding assemblies. The 19S-20S-19S assembly is known as the 26S proteasome, a giant enzyme complex of 2.5 MDa (Fig. 1D). The core needs to be decorated by at least one cap to recognize, bind, and process the UPP substrates marked for degradation by polyubiquitin chains. The 19S resists crystallization attempts; however, detailed models based on cryoEM and molecular modeling have been recently proposed (30, 79, 80). The 19S cap is built from 18 constitutive subunits, forming the base and lid subcomplexes (45). The eight “Rpn” (RP non-ATPases) subunits of the lid, Rpn3, Rpn5-Rpn9, Rpn11, and Rpn12, are responsible for binding the substrates and removing the polyubiquitin chains. The base subcomplex consists of six AAA ATPases termed Rpt1-Rpt6 (RP ATPases), and four non-ATPase subunits Rpn1, Rpn2, Rpn10, and Rpn13 (30, 36, 79). The ATPases form a ring or a “spiral staircase” structure, work as reverse chaperones, unfold the protein substrates, open the gate, and direct the substrates to the core for proteolytic processing (9). In addition to the constitutive subunits, several other proteins, among them being substrate-bringing vehicles, deubiquitinating enzyme or ubiquitin ligase, can transiently bind to the 19S (23, 28, 44, 57). These additional constitutive or transient protein ligands can supplement the enzymatic cap-

abilities of the proteasome by extra ATPase, protease, or ligase. Clearly, the proteasome is an extraordinary complex enzyme assembly, in both structural and functional aspects. It is, thus, not only an attractive but also a challenging subject for studies on allostery.

The Proteasome As an Allosteric and Dynamic Protein Assembly

The structural organization of the core proteasome as a compartmentalized enzyme assembly with multiple active centers lends itself to widespread involvement of allosteric interactions, which are unequivocally connected to structural dynamics. This is in stark contrast to the manner in which the proteasome has been presented for many years as a static and non-allosteric molecule (11). Moreover, the proteasome has been contrasted with chaperonins of similar size and shape, but with robust molecular dynamics, such as GroEL (22, 116, 136). Nevertheless, evidence of allosteric regulation of the proteasome abounds is provided by several diverse methods, including biochemical activity tests, atomic force microscopy (AFM), nuclear magnetic resonance (NMR) spectroscopy, and EM. Starting with the classical biochemistry, analysis of enzyme kinetics for three proteasome peptidases indicates that the active centers are bound in a web of interactions, from positive cooperativity of the two ChT-L sites to complex activation/inhibition schemes possibly involving noncatalytic substrate binding sites (70, 91, 98). Putative

allosteric sites are also involved in actions of a leading anti-AIDS drug, ritonavir that is designed to block essential peptidase of the human immunodeficiency virus (HIV) impairing its ability to replicate. Apparently, ritonavir inhibits the core 20S with a unique noncompetitive-competitive, allosteric-involving mechanism of action (119).

Activation of the 20S core on binding the PA28/REG is also an allosteric process. The increase in activity may be simply explained by gate opening and indiscriminate, increased influx of substrates. The very diverse effects of PA28 $\alpha\beta$ and PA28 γ on the three peptidase activities of the core, however, are better explained by allosteric interactions (109, 110).

In fact, the gate opening provides an excellent example of allosteric signaling and molecular dynamics. The first crystal structure of the core proteasome was solved for the archaeobacterial 20S, homologous but simpler than the eukaryotic 20S particle (85). The general architecture of the *Thermoplasma acidophilum* proteasome is very similar to the eukaryotic 20S core; however, the former is built from only one kind of α and one kind of β subunits. The homoheptameric α ring apparently does not support a full protection of the central channel: The structural model presents an always-open entrance to the inner compartment (85). Analysis of the primary structure of eukaryotic α subunits reveals that they evolved to include “extensions” of N-termini. Indeed, the center of the α face is sealed by tightly interwoven N-terminal “tails” of α subunits in the crystal structure models of both yeast and mammalian CPs (50, 63, 130). This finding at first created serious confusion, as it was not apparent if and how the tails may loosen up, nor where the true entrance used by the substrates was. The widely used *in vitro* method of “activation” of the core by treatment with a low concentration of detergent sodium dodecyl sulfate was hardly transferable to the natural conditions. However, subsequent crystal

structures of the yeast 20S core activated by gate-disrupting mutation (48) or by the attachment of PA26, a homolog of PA28 (134), revealed the open gate and unobstructed entrance to the central channel. Simultaneously, AFM imaging demonstrated not only that the open-gate conformation exists, but also that the gate is dynamic with every single proteasome molecule able to switch constantly between the closed and open conformations (Fig. 2) (99).

AFM Is an Excellent Technique to Study Protein Dynamics

AFM belongs to the group of scanning probe microscopies (SPM) where an image is created based on interactions of the scanning probe with the surface on an imaged object. AFM is the most popular among the SPM methods used for biological applications (34, 38). In the noninvasive oscillation (tapping) mode AFM, a very small and sharp probe (“tip”) mounted on the cantilever oscillates above the object (for example, a protein molecule), scanning it in a raster motion (Fig. 2A). The object to be scanned needs to be immobilized; however, this can be achieved in a very gentle way by simply depositing the molecules on a weakly charged, flat, and clean surface such as freshly cleaved mica (39). The probe is positioned close enough to communicate with the surface atoms of the molecule, mostly by van der Waals interactions. The probe oscillations are modified as a result of variations in the distance between the tip and the scanned sample. The feedback loop between a sample/tip positioning system and a computer-controlled piezo element constantly corrects the set distance. The image of the sample’s surface has three-dimensional topographical information and is generated by plotting the z (vertical direction) correction signal from the feedback loop against the x and y plane (34). There is no

FIG. 2. AFM imaging reveals conformational diversity of the 20S proteasome. (A) A scheme of AFM imaging: A sharp probe (tip) mounted on a cantilever and controlled by a piezo element maintains van der Waals distance from the scanned sample, in this case 20S proteasome molecules attached to a mica surface. As a result, topography of the upper part of the molecule is rendered. Left insert marked with an arrow: An AFM image shows the 20S proteasome α face in the open-gate conformation; right insert marked with arrow: a tilted view of a fragment of densely populated field of human proteasomes. (B) Top view Images of open-gate and closed-gate human 20S proteasomes. The diagram on the right demonstrates how the central sections in four directions (a–d) were carried out to distinguish between the closed (all sections convex) and open (all sections with a dip) conformers. The actual sections, about 1 nm from the top, are presented below the respective images. (C) Time-lapse images of a single 20S particle scanned every 4 min. Sections (a, c; see earlier) through the topmost part of the α ring are provided below each image. The particle apparently was switching between the open (time points: 0, 28, 32 min.) and closed conformations. Reproduced (B) by permission from Osmulski and Gaczynska (102) modified. Adapted [(C), inserts in (A)] with permission from Gaczynska *et al.* (37) Copyright 1993 American Chemical Society. AFM, atomic force microscopy.

electromagnetic wave-dependent limitation of resolution of the imaging. The practical resolution for biomolecules depends on the size and shape of the tip, the quality of electronics, and the dynamics of the object, and reaches 0.1 nm in vertical and 1 nm or less in lateral directions (101). Nanometer-scale allosteric motions, especially in large molecules, are perfectly within the range of detection by AFM. The advantages of the method include the opportunity to monitor in real time changes of the topography of live molecules in liquid. Detecting the spontaneous opening and closing motions of the gate demonstrates the conformational diversity of the proteasome core (Fig. 2B, C). Moreover, the gate area is not the only dynamic part of the molecule. Analysis of lateral dimensions of the particles reveals that they assumed either barrel-like (short and wide) or cylinder-like (long and narrow) shapes, correlating with the gate closing and opening (100). Apparently two forms of particles with well-distinguishable structural features remain in equilibrium with the prevailing closed gate, barrel shaped, and less populated open gate, cylinder shaped (100). The partition of conformers, about 75% (closed) to 25% (open), indicates a relatively small difference in the free energy between the two conformers, as even the less populated state is readily detectable (100). Still, the crystal structure of the free, wild-type core captures the more stable and thus more populated, closed-gate conformer (50). Importantly, the dynamic nature of the entrance to the central channel has been confirmed by NMR spectroscopy of the archaeobacterial core (111). NMR is usually used to study dynamics of much smaller proteins; however, the homooligomeric architecture of archaeobacterial proteasome rings enabled to overcome the size limitations (125). Even if the archaeobacterial gate is rudimentary, it still provides a movable barrier sequestering larger substrates (124), a startling example of the long evolutionary history of the concept of dynamic gating. Coming back to the elegant NMR studies, the most recent data demonstrated the conformational diversity of the archaeobacterial proteasomes, which is in full agreement with the AFM imaging (114).

The significance of dynamic gating and conformational diversity for catalysis is obvious: The inactive (latent; closed-gate) proteasome core periodically opens and accepts substrates. Moreover, AFM imaging combined with biochemical and mutational studies reveals a positive feedback loop between catalysis and gate opening. Apparently, a tetrahedral transition state in a catalytic center sends an allosteric signal to the gate, promoting its opening (103). Thus, while supplies last, the next substrate molecule can enter the proteasome inner compartments, proceed to degradation, and promote gate opening for the subsequent substrate molecule. The process is mediated by the amine group of the catalytic N-terminal threonine, and it can be provoked not only by substrates but also by inhibitors mimicking the tetrahedral transition state, such as bortezomib, and by certain active site mutations (103). Here, the orthosteric site performing its catalytic duties acts at the same time as an allosteric site, sending signals to a distant gate. Binding of a substrate or a certain inhibitor shifts conformational equilibrium of the proteasome population toward more of the open conformers (103). We may speculate that random molecular reorganizations in the active site area are responsible for the closed-open switches in the absence of a specific ligand. It is reasonable to speculate that the same or similar allosteric route, from the

active sites to the α face, is used in another phenomenon, which is the stabilization of 26S proteasome observed on bortezomib treatment (72).

The structural integrity of 26S assembly is controlled at several levels, with most, if not all of them, clearly involving allostery. Biochemical methods and EM have been used to propose a model of allosterically driven disassembly of the 26S, controlled by ATP hydrolysis and correlating with the catalytic cycle (6). This model remains controversial, and results of a distinct set of experiments under different conditions failed to support it (74). However, the idea of periodic lowering of the affinity between the core and the cap may still be viable. The reverse-chaperone and polypeptide-translocase activities of the 19S base ATPases are expected to involve robust mechanical interactions between the substrate, the base, and the 20S core (61, 88, 124). Focusing on the base-core interface, the most striking effect of the base attachment is gate opening (123, 124).

Earlier, we discussed the allosteric gate opening “from the inside” responsible for conformational diversity as well as effective catalysis by the 20S core. Attachment of regulatory modules to the α face opens the gate “from the outside” (115, 123, 134). All the modules dock in the grooves positioned between α subunits, halfway from the gate to the rim of α ring (Fig. 1) (115, 123, 134, 137). The 2–3 nm long distance between the binding grooves and the effector site (the pivot residues of the gate forming tails of α subunits) invokes allosteric signaling as the cause of gate opening “from the outside.” One more class of ligands proposed to induce gate opening are hydrophobic peptides (71). These peptides may bind to several new allosteric sites (71). Alternatively, they may utilize the canonical grooves on the α face, the substrate binding pockets in the inner compartments of the core, or serve as substrates, triggering gate opening “from the inside.”

The movements related to opening and closing of the gate are not restricted to the gate-forming N-terminal tails of α subunits. An analysis of cryoEM images of the 26S proteasomes reveals radial displacements of α subunits, postulated to open the gate (31). Interestingly, we observe a similar phenomenon, manifested by a significantly increased diameter of the top of α ring, in the AFM images of open-gate conformation of the 20S core (Gaczynska and Osmulski, Unpublished observations). Apparently, multisubunit rings of the 20S core and the 19S base are conformationally diverse. The dynamic changes in the α ring and ring of ATPases may stand behind the first observed case of multiple conformational forms of the proteasome assembly, the “wagging” of 19S cap in 26S. The “wagging” was reported after analysis of three-dimensional EM images, clearly showing distinct positioning of the 19S relative to the 20S core (80). The different poses might have been artifacts forced by fixing of the molecules for EM imaging. However, even more robust bends of the 26S structure were observed by AFM, with unfixed, live molecules, lightly immobilized and submerged in a buffer (38). It is tempting to speculate that “wagging” is a manifestation of conformational diversity of the 26S proteasome, and that substrate processing is tied to conformational changes. Indeed, a recent report presents an elegant model of the 19S cap dynamics, involving twisting motions of the ring of ATPases, periodic widening of the ring’s pore, and exposure of the Rpn11 deubiquitinylase, all of which facilitate the processing of polyubiquitinated proteins (86).

Summarizing, the proteasome assemblies appear dynamic and highly allosteric. The so-far described cases of molecular dynamics and allosteric regulation follow modern views on conformational diversity, population shifts, and dynamics driven catalysis. For now, we can distinguish several allosteric routes between distant parts of the assemblies. Some of the routes can be utilized by small-molecule ligands. We will discuss these next.

Proteasome Inhibitors: The Blockers of Catalytic Centers

Development of inhibitors specific to the proteasome played a pivotal role in establishing the physiological significance of the UPP (see Soriano *et al.*, this Forum). Some of the common inhibitors targeting active sites of multiple serine or cysteine proteases; for example, leupeptin (*N*-acetyl-Leu-Leu-Arg-aldehyde) (135) or 3,4-dichloroisocoumarin (98) affect proteasome activities. Their value, however, in *in cellulo* or *in vivo* studies is obviously limited. Since the first reports in the early 1990s, that small-molecule inhibitors show reasonable specificity toward the proteasome, seven drugs have been already approved or tested in humans. All of these drugs are covalent, competitive inhibitors that primarily target the $\beta 5/\beta 5i$ active sites which are responsible for the “workhorse” post-hydrophobic (ChT-L) cleavages (14). These new drug developments are based on the serendipitous observation that hematological cancer cells, for example in multiple myeloma and lymphoma, are exceptionally sensitive to blocking the UPP and respond by the induction of apoptosis (1, 33). Several proteasome-specific competitive inhibitors that differ in their chemical mechanism of action to block the catalytic centers are currently used in research (Fig. 3A). These are also under scrutiny as possible treatments for human cancers and other diseases. Two proteasome-targeting drugs are currently approved by the FDA. The first, bortezomib (Velcade, MLN-314; Millenium Pharmaceuticals, Inc.) is a dipeptidyl boronic acid (pyrazylcarbonyl-PheLeu-boronate; Fig. 3B) (2); whereas the second FDA-approved drug is carfilzomib (Kyprolis; Onyx Pharmaceuticals), an

epoxyketone derivative. Two other boronates, ixazomib and delanzomib (Millenium Pharmaceuticals, Inc. and Cephalon, respectively), as well as two other epoxyketone derivatives (epoxomicin and oprozomib) (Fig. 3C) (76, 106), and a lactone derivative, marizomib (NPI-0052; Nereus Pharmaceuticals), are currently undergoing clinical trials (Fig. 3D) (16).

Many of these inhibitory compounds are using “warheads” developed for serine or cysteine proteases. In such cases, the proteasome specificity is bestowed by the peptide or peptidomimetic moieties that are designed to fit in the substrate-binding pockets (13). Peptide aldehydes, vinyl sulfones (VSs), and boronates belong to this group. Examples of such inhibitors include carbobenzoxy-Leu-Leu-Leucinal (MG132) (112), carbobenzoxy-Leu-Leu-Leu-VS (12), or carbobenzoxy-Leu-Leu-Leu-boronate (MG262) (72), all of which have the same peptide moiety but distinct pharmacophores, and all primarily target the $\beta 5/\beta 5i$ active sites. Changing the moiety attached to the pharmacophore alters the affinity of the inhibitor to the distinct active centers. A notable example is provided by a derivative of the familiar Leu-Leu-Leu-VS sequence that is extended by aminohexanoic acids (Ahx) and blocked with adamantanyl acetate (Ada): Ada(Ahx)₃LLL-VS and binds to all three kinds of active sites with a similar affinity (67). Inhibitors targeting primarily post-acidic or post-basic cleavages are less frequently used than those binding to the ChT-L active sites, and they are mostly represented by VS and epoxyketone derivatives (15, 53, 91, 93, 132). The use of α',β' -epoxyketone derivatives as proteasome inhibitors started with the natural antibiotics eponemycin and epoxomicin (78) and later evolved into an important drug development enterprise (76, 106). The exceptional specificity of epoxyketones as inhibitors of proteasome function exploits the rare N-terminal nucleophile catalytic mechanism of the proteasome: The compounds engage both amino and hydroxyl groups of the active site Thr1, whereas most of the other inhibitors target the Thr1 hydroxyl (51). The greater specificity of carfilzomib and other epoxyketone-based drugs renders their use to be more advantageous than that of bortezomib. The boronate warhead of bortezomib is highly reactive and

FIG. 3. Structures of selected proteasome inhibitors used in human cancer treatment. (A) A section through a side-view model of the 20S proteasome structure (50). Asterisks mark approximate positions of three out of six active sites in the catalytic chamber where the inhibitors bind. (B) FDA-approved dipeptide boronate bortezomib (MLN-314; VelcadeTM). (C) FDA-approved tetrapeptide epoxyketone carfilzomib (PR-171; KyprolisTM). (D) Lactone derivative marizomib (NPI-0052; salinosporamide A). The “warhead” groups of the compounds are marked with brackets.

unfortunately also reacts with nonproteasomal targets, contributing to several adverse side effects (4) (see also Drews and Taegtmeyer, this Forum). Interestingly, the exquisite specificity of epoxyketones can go as far as strongly preferring the immunosubunit $\beta 1i$ (low molecular weight protein 2) to the housekeeping $\beta 1$ (Y) (60).

The lactone-derivative class of competitive proteasome inhibitors warrants special attention. The first extensively studied compound from this group is derived from a natural fungal antibiotic lactacystin (omuralide). This, when in aqueous environments, rearranges its structure into clasto-lactacystin β -lactone, which is capable of blocking Thr1 hydroxyl. Lactacystin was pivotal in the discovery of the catalytic mechanism of the proteasome (29). Interestingly, prodrugs for statins, used in the treatment of hypercholesterolemia, weakly target the proteasome with their lactone rings (90). Lactone rings are common in many natural products and these may work as unsuspected proteasome inhibitors. Similarly, plant polyphenols, which are abundant in numerous nutraceuticals and in green tea, may block proteasome in a manner resembling lactones (92). Relatively recent additions to the family of proteasome inhibitors are syrbactins, which are bacterial products. These cyclic peptides are highly specific ligands of the $\beta 5$ active site (54, 73) and extremely potent proteasome inhibitors. The proteasome inhibiting compounds mentioned earlier directly engage catalytic threonine, whereas several inhibitors are known to occlude the active sites without binding to Thr1. These include fungal product gliotoxin (75), and cyclic peptide fungal metabolites from the TMC series, such as TMC-95A and others (52). The end product of lipid peroxidation, 4-hydroxy-2-nonenal (HNE), also strongly, albeit nonspecifically, modifies the proteasome, with deleterious effects on catalytic activity (96). Gliotoxin, TMC peptides, or HNE likely do not directly involve the allosteric effects.

This brief overview of the best-known proteasome inhibitors will not be complete without mentioning the synergistic effects displayed *in vivo* by their combination. This phenomenon was noted for bortezomib and marizomib (17), and also for bortezomib and delanzomib (117). Moreover, carfilzomib and other new generation proteasome targeting drugs are capable of overcoming the common phenomenon of bortezomib resistance in cancer cells (76, 106). The effect of synergy may stem from slightly distinct specificities of the different drugs. All of them target primarily the ChT-L activity; however, these also target other catalytic sites, although their second-choice active site preferences are different. These secondary actions apparently translate into induction of separate apoptotic pathways (17). The structural diversity of the various proteasome inhibitors is likely pivotal in overcoming resistance to bortezomib, especially if the resistance is caused by a mutation in the active site (35, 128). The occurrence of such mutations brings into the spotlight the well-known deficiency of all drugs binding to active centers of enzymes: Sooner or later, a mutation may occur, rendering a drug unusable.

Proteasome Regulators: Beyond the Catalytic Centers

Given the undisputed clinical successes and number of known proteasome-inhibiting compounds as well as the level of structural and functional knowledge of their mechanism of action, it is not surprising that drug development has focused, to a

large extent, on mechanisms that block the active centers of the proteasome. However, the diversity of such inhibitors pales in comparison with potential allosteric regulators. The term "regulators" is broadly used to indicate non-straightforward functional effects of these ligands. For example, they may activate latent 20S proteasomes and inhibit the activated 20S cores. The three major peptidase activities may respond in distinct ways to allosteric regulators: One peptidase may be activated and another may be inhibited by the same compound. In addition to or instead of influencing peptidase activities, the ligands may interfere with interactions between the CP and regulatory modules. The variety of *in vitro* detectable actions translates into intriguing physiological outcomes in cultured cells or in animal studies; for example, a substrate-specific inhibition. Substrate-specific activation may be of high interest to prevent accumulation and aggregation of polypeptides causing cell damage in neurodegenerative and other aggregation diseases (see McKinnon and Tabrizi, this Forum). On one hand, the expanded arsenal of effects promises precise tailoring of pharmacological interventions within the UPP. On the other hand, the limited knowledge about proteasome allostery complicates the task of designing allosteric drugs. Fortunately, recent years brought a significant advance in mapping the allosteric routes in the 20S core proteasomes and challenging them with small molecules, usually binding in a non-covalent, fully reversible manner. Next, we present the better traveled allosteric routes and the respective ligands.

Allosteric Route: From the Catalytic Centers to the Grooves on α Face

As outlined earlier, substrates and certain competitive inhibitors binding to orthosteric sites may double as allosteric ligands, promoting opening of the gate (99, 100, 103). Gate opening can be detected by AFM imaging of the 20S core and confirmed by functional studies of the latent or allosterically open core decorated with 11S activator (103). Interestingly, inhibitors promoting gate opening such as bortezomib and epoxomicin support stability of the 26S assembly, and serve as an elegant example of long-distance signaling between the active centers and the grooves used to anchor the 19S module (72). It is tempting to speculate that the same molecular route from the active sites is used to reach the grooves and the gate, both of which are positioned on the α face. The significance of this route for drug design is yet to be evaluated. By now, it appears to be safe to assume that blocking the workhorse ChT-L catalytic site by boronates or epoxyketones results in much more dramatic effects in cellular physiology than stabilization of the 26S assembly. However, mapping the relevant allosteric route may enable the design of specific small-molecule regulators targeting yet-undiscovered allosteric sites between the catalytic centers and the grooves. Such regulators would affect the stability of higher-order proteasome assemblies without blocking the active sites, and, thus, would provide very precise means to intervene into the UPP performance.

Allosteric Route: From the Grooves on α Face to the Gate

The surface of the α ring is not only conveniently flat to avoid steric hindrance with large protein ligands, but also equipped with anchor sites for securing the protein-protein interactions. As mentioned earlier, the sites are in the form of

FIG. 4. Targeting the “grooves to the gate” allosteric route. (A) The top view of α face with positions of grooves between α subunits circled and the gate area marked with an *asterisk*. (B) Amino-acid sequences of selected C-terminal fragments of human proteins anchoring into the grooves, and the peptide derived from the PA28 α activation loop. The HbYX motifs are underlined. (C) Amino-acid sequences of Tat1 and Tat2 peptides derived from the RTP site of HIV-1 Tat protein (65). (D) Structures of rapamycin (sirolimus), its single-domain derivative pimecrolimus, and its first metabolite, *seco*-rapamycin, which are unexpected allosteric ligands of the 20S proteasome. (E) Rapamycin and its derivatives affect the conformational dynamics of α face. *Left*: a gallery of zoomed-in images of the control human 20S proteasomes treated with DMSO solvent (*top*) and proteasomes treated with up to 5 μ M of rapamycin. All image squares are 15 $\times$ 15 nm. The partition between closed:open conformations changes from 3:1 to 2:3. *Right*: proteasomes treated with the saturating concentration (10 μ M) of rapamycin, pimecrolimus, or *seco*-rapamycin display the 2:3 (closed:open) partition of conformational forms and are refractory to conformational shifts induced by a peptide substrate (SucLLVY-MCA; 100 μ M) (102). Reproduced (E) by permission from Osmulski and Gaczynska (102), modified. DMSO, dimethylsulfoxide; Hb, hydrophobic amino-acid residue; HIV, human immunodeficiency virus; HIV-1 Tat, human immune deficiency virus type 1 transactivator; MCA, 7-amido-4-methylcoumarin; RTP, REG/Tat-proteasome binding; Suc, succinyl; Tat, transactivator.

grooves positioned on the interfaces of α subunits, about halfway between the gate and the rim of α ring (Fig. 4A). The grooves are similar but not identical and may display certain levels of specificity or redundancy, depending on the ligand. Most of the protein ligands, the Rpt2, Rpt3, and Rpt5 ATPases of the 19S base; PAN ATPases in Archaeobacteria; the PA200 (Blm10) activator; and, most likely, the PI31 inhibitor utilize the C-terminal hydrophobic amino-acid residue (Hb)YX motifs (hydrophobic amino acid–Tyr–any amino acid) for secure docking in the grooves (Fig. 4B) (115, 123). The 11S activator is the sole exception to the HbYX rule. Subunits of PA28/REG and homologous PA26 insert their C-terminal fragments to the grooves; however, the HbYX motifs are not present and the binding is stabilized by interactions between the activation loops of each 11S subunit and the α face, near the respective grooves (Fig. 4B) (32, 134). Remarkably, short fragments of the original “anchors” can mimic some functional effects of the activators. These

observations strongly suggest that allosteric switches are positioned in the grooves and are flipped on binding of the HbYX motif. Indeed, as little as ten C-terminal amino-acid residues of Rpt2, Rpt5, PAN ATPase, PA200, or PI31 are sufficient to enhance at least some peptidase activities (Fig. 4B) (43, 123) (Madabhushi, Osmulski, and Gaczynska, Unpublished observations). Moreover, treatment of the proteasome with the C-terminal peptides derived from Rpt5 or PI31 shifts the conformational equilibrium of the 20S core toward more of the open particles, as revealed with AFM imaging (Osmulski and Gaczynska, Unpublished observations). The presence of HbYX motif does not guarantee modulation of peptidase activities. The Rpt3 ATPase possesses the same motif and binds to the α face; however, it is implicated in stability of base-core interactions rather than activation of the core (77, 123). Interestingly, the HbYX motif is not unconditionally required for the peptide-induced, groove-related effects on the peptidase activities. Treatment of

the human 20S proteasome with a combination of 12-residue peptide fragments derived from the C-terminus and from the activation loop of PA28 subunit (Fig. 4B) resulted in more than 50% activation of the post-hydrophobic cleavages, even if the peptides were present at as low concentrations as 0.5 μ M each (65). These results suggest that both the stable binding of the 11S and its allosteric effects require both the C-terminal and activation loop components.

The C-terminal "tail" peptides of regulatory modules have not been modified to enhance their performance, with the exception of a brief attempt to mix and match their HbYX-containing fragments (77) (Tokmina-Lukaszewska, Gaczynska, Osmulski, and DeMartino, Unpublished observations). Moreover, the structures of C-terminal tails of PA28 subunits do not seem to determine their functional specificity, hampering the design of peptides that modulate the proteasome peptidase activities (81). Most importantly from the practical point of view, the groove-binding peptides in their present form would be likely rapidly degraded in the cytosol before even reaching the proteasome. Fortunately, the high propensity to degradation is not of particular concern in the case of another family of small ligands of the proteasome, the transactivator (Tat) peptides (Fig. 4C). Tat peptides are fragments of human immune deficiency virus type 1 transactivator (HIV-1 Tat), an 86-residue RNA-binding protein that is responsible for transactivation of viral and certain host genes. The poorly structured HIV-1 Tat forms a homoheptameric complex, affects angiogenesis and the immune response, and inhibits ChT-L activity of the proteasome (10, 42, 64, 120). HIV-1 Tat can reportedly interact with multiple α and β subunits of the 20S core (3); however, it is reasonable to assume that the high-affinity binding is related to the REG/Tat-proteasome binding (RTP) site present in the HIV-1 Tat (62). The functional RTP site is shared by HIV-1 Tat and PA28 α subunit and, consequently, the Tat protein competes with 11S for binding to the α face (62, 120). Even if the direct structural identification of the docking place of HIV-1 Tat is missing, we may hypothesize that it is positioned in or in the close vicinity of α face grooves. The RTP site is located near the C-terminus in PA28 α , whereas it encompasses the essential basic domain of the viral protein in HIV-1 Tat (65). Highly basic peptides derived from the Tat protein are used for a variety of tasks, including the transport of cargo molecules through the membrane (68); however, here, we focus on their proteasome-targeting ability. The two 12-residue fragments (Fig. 4C) containing the RTP site and carved out of the basic domain (Tat1), as well as the basic and Gln-rich domains (Tat2) of HIV-1Tat noncompetitively inhibit the ChT-L and PGPH peptidases of the activated human 20S core at high nanomolar concentrations, and also efficiently compete with the core activation by PA28 $\alpha\beta$ complex (65). The Tat1 peptide is better characterized to date than Tat2. Tat1 induces a shift toward the higher abundance of the open conformer in AFM studies. It also inhibits the ChT-L peptidase of the latent 20S, and strongly affects the pattern of degradation products of poorly structured proteins (65) (Karpowicz, Gaczynska, and Osmulski, Unpublished observations). The affinity of Tat1 to the proteasome can be improved by modifying its structure with non-natural amino acids (Karpowicz, Jankowska, Gaczynska, and Osmulski, Unpublished observations). The intracellular effects of Tat1 and its derivatives are currently under vigorous investigation.

The small peptide ligands of the α face grooves described earlier are derived from natural protein ligands of the 20S core. The ligand described next breaks this rule: It is not a peptide and is not based on a natural proteasome ligand. This compound rapamycin (sirolimus) is a canonical allosteric drug, inducing dimerization of a pivotal regulator of intracellular metabolism mammalian target of rapamycin (mTOR) and FK-binding protein 12 (Fig. 4D). This natural macrocyclic inhibits mTOR by binding to its allosteric site, located near the kinase domain containing the orthosteric site (8). The binding domain of the macrocyclic ring interacts with mTOR, whereas the effector domain recruits FKBB12 (8). *In vivo* treatment with rapamycin induces numerous pleiotropic effects, including immunosuppression, proapoptotic and anti-cancer actions, as well as prolonging longevity (55, 58, 133). *In vitro*, at low micromolar concentrations rapamycin inhibits the degradation of casein, a poorly structured protein, by the latent human 20S core (102). The various peptidase activities of the 20S core respond to varying concentrations of rapamycin differently. At high nanomolar concentrations of rapamycin, post-acidic cleavages are inhibited by a noncompetitive mechanism. At low micromolar concentrations, the ChT-L peptidase is strongly inhibited, while the T-L peptidase activity is increased two-fold (102). Interestingly, rapamycin abolishes activation of the 20S core by 19S complex or by peptides containing the HbYX motif. The most straightforward explanation of the finding would be competition of rapamycin and the peptides for binding to the α face (102). Indeed, molecular modeling strongly suggests that rapamycin may fit very well into selected grooves on the α face (Bohmann, Gaczynska, and Osmulski, Unpublished observations). Moreover, treatment with the drug affects conformational dynamics of the α face. AFM imaging of the human 20S proteasomes revealed that rapamycin shifts the conformational equilibrium toward a higher abundance of the open particles (Fig. 4E) (102). We speculate that on docking to the α face, rapamycin exploits the allosteric route used by gate-opening regulatory modules. There is one more intriguing aspect of the conformational dynamics related to effects of rapamycin. Treatment of the 20S core with the saturating concentration of a model peptide substrate induces maximum 75% of the open particles (99, 100, 103). A saturating concentration of rapamycin pushes the equilibrium to about 60% of the open proteasomes. When the rapamycin-treated 20S proteasomes are subsequently treated with a substrate, the partition of open and closed forms stays at 60% and 40%, respectively, and does not shift to 75% and 25%, even if the active sites of the core are not directly blocked and, thus, ought to be capable of engaging substrates (Fig. 4E) (102). The nature of the link between apparent rapamycin-induced perturbation in conformational dynamics and the effects on proteasome catalytic activity is purely speculative at this point. There may be a direct allosteric communication between the binding groove and the catalytic sites, perhaps independent from gate opening. On the other hand, there may be an allosteric link between the gate and the catalytic sites, involving the dynamics of gate movements. Such a link could be far more complex than a non-allosteric effect of increased flux of substrates through a longer open gate. Dissecting the structural and functional effects of rapamycin-proteasome interactions is of great value for learning about the role of allostery in proteasome

function. The difference in *in vitro* affinities of rapamycin to mTOR and also to the proteasome definitely favors the former as the primary, in practice the sole, *in vivo* target of the drug. It is likely that close homologs of rapamycin, rapalogs, and single-domain derivatives of rapamycin, such as pimecrolimus (Fig. 4D), will affect proteasome function using similar pathways to those outlined earlier. However, there is a great opportunity to design “rapamycin-inspired” ligands specific to the proteasome. Apparently, the first *in vivo* metabolite of rapamycin, the open-ring *seco*-rapamycin (Fig. 4D), exerts similar effects to those of the parent drug on the proteasome while not inhibiting mTOR activity (102). Pilot tests indicate that *seco*-rapamycin is cytotoxic to those cells which are resistant to bortezomib treatment (Osmulski and Gaczynska, Unpublished observations). Studies are in progress to identify the proteasome targeting pharmacophore of rapamycin and *seco*-rapamycin, and to utilize this in the design of a new class of allosteric proteasome regulators.

Allosteric Route: From the Outer Rim of α Ring to the α Face

The grooves on the mid-region of α face are universally used by protein regulators of the proteasome (115, 123, 134). There are no known physiological ligands of the outer rim of α ring; however, the rim may bear a binding site for proline- and arginine-rich (PR) peptides. PR peptides are allosteric ligands that are derived from an antibacterial peptide from the cathelicidin family (Fig. 5A). Cathelicidins are a part of innate immune response of mammals, killing bacteria by a non-pore forming mechanism (19). The effects of PR peptides on the proteasome were first reported with PR39, a 39-residue-long peptide from a porcine intestine with no known homologue among human cathelicidins (Fig. 5B). *In vitro*, PR39 inhibits the ChT-L and PGPH activities of purified activated 20S proteasome in a noncompetitive manner. The N-terminal

arginines of PR39 are essential for these biological effects (37). PR39 also competes with the 19S cap binding to the 20S core and inhibits the already assembled 26S proteasome (37). Importantly, PR39 can be shortened to only 11 N-terminal residues (Fig. 5B) without any loss of function, although some loss of affinity is evident (37). Yeast two-hybrid screen, molecular modeling, and cross-linking/mass spectrometry studies indicate that the binding site for PR peptides is the C-terminal part of the $\alpha 7$ subunit, positioned on the outer rim of α face (41) (Osmulski, Gaczynska, Tokmina-Lukaszewska, Slusarz, and Slusarz, Unpublished observations). Interestingly, AFM studies revealed that PR peptides structurally destabilize the α face. Instead of the well-distinguished conformers, images of the 20S particles treated with PR39 or PR11 show a “shaky” α face with a partially open gate (Fig. 5C) (37). Structural destabilization was not restricted to the core, but was apparent for the 26S proteasome treated with PR peptides as well (Fig. 5C) (37). We hypothesize that there is an allosteric route extending from the $\alpha 7$ C-terminus into the whole α face. The PR peptides disrupt this route, affecting dynamics of open–close switches. Such destabilization of the α face is likely a culprit in a lowered affinity between the 20S and 19S subassemblies, and in the striking disruption of the 26S super-assembly (Fig. 5C). The drastic changes in molecular dynamics of the α face may account for all the observed effects of PR peptides on catalytic activity. However, the existence of an additional allosteric route between the rim of α ring and the catalytic chamber is still possible. These intriguing molecular effects may be accompanied by *in vivo* actions of considerable pharmacological interest. The strongly basic PR peptides readily traverse cell membrane. Higher nanomolar to lower micromolar concentrations of the compounds are required both *in vitro* and *in cellulo* to demonstrate effects of treatments (41). PR peptides have likely additional intracellular targets besides proteasomes (108); however, their directly proteasome-related actions include

FIG. 5. Targeting the “rim to the α face” allosteric route. (A) The top view of α face with the C-terminal part of $\alpha 7$ (the outer rim of α ring) circled and the gate area marked with an asterisk. (B) Amino-acid sequence of PR39 peptide. The 11-residue N-terminal fragment of PR39, PR11, is underlined (37). (C) PR peptides affect conformation of the 20S and 26S proteasomes. Left: a gallery of AFM top-view images of human 20S proteasomes, control or treated with 5 μ M PR11. Right: AFM side-view images of a human 26S proteasome particle, control (with an outline) and after treatment with 1 μ M of PR39. The unusual shape of the particle, featuring “enlarged” (more dynamic?) 19S caps, was apparent when the same particle was scanned and imaged shortly (4 min) after treatment or 48 min after treatment. The 10 nm scale bar refers to both panels. PR, Pro- and Arg-rich peptides. Adapted (C) with permission from Gaczynska *et al.* (37) Copyright 1993 American Chemical Society.

blocking the degradation of two key transcription factors: hypoxia-inducible factor (HIF)-1 α and inhibitor of κ B, where NF- κ B is nuclear factor kappa-light-chain-enhancer of activated B cells; I κ B, without detectable attenuation of the whole UPP (41, 82). HIF-1 α is a regulator of intracellular oxygen distribution, and its accumulation induces angiogenesis (82). Stabilizing I κ B, in turn, has anti-inflammatory effects, as I κ B blocks nuclear factor- κ B, the master regulator of inflammation (41). This seemingly substrate-specific inhibition remains unexplained; however, the potential clinical value of the phenomenon is immense. The beneficial effects of PR peptides in animal studies include improved wound healing and protection of the brain and heart from inflammation-driven deleterious effects of ischemia–reperfusion injury after stroke or heart attack (41, 82) (see also Drews and Taegtmeier, **this issue**). Modifications of the structure of PR11, for example by including peptidomimetics, increase specificity and affinity of the ligand toward the proteasome (Osmulski, Gaczynska, Juszczak, and Sosnowska, Unpublished observations). PR peptides and their derivatives seem underestimated as drug leads, and are still waiting for their prime time.

Allosteric Route: From the Interface of α and β Rings to the Antechamber

As in the case of the allosteric site on the C-terminus of α 7 subunit, the interface of α and β rings have no known physiological ligands. However, NMR studies on the allostery of *Thermoplasma* proteasome performed on the complete core complex, the “half proteasome” dimer of α rings, or a single homoheptameric α ring demonstrated that chloroquine, a well-known anti-malaria drug, binds in this region (Fig. 6A, B) (126). A relatively large negatively charged area in the vicinity of α Ile157 was identified as the site of drug-proteasome interactions, possibly stabilized by hydrogen bonds. Interestingly, the lining of the antechamber is affected by the binding of chloroquine, clearly indicating a novel allosteric route (Fig. 6A) (126). *In vitro*, chloroquine at millimolar concentrations inhibits the degradation of model peptide substrates and disordered proteins (114, 126). The affinity of chloroquine to the eukaryotic or archaeobacterial 20S cores is rather low; however, a screen of chemical library of compounds with a quinoline pharmacophore turned in 5-amino-8-hydroxyquinoline (5AHQ) as a viable candidate

for proteasome targeting allosteric drug (Fig. 6B) (83). NMR studies indicated that 5AHQ binds to the archaeobacterial proteasome in the region identical or very similar to that identified for chloroquine, and that antechamber is affected by the binding, as was the case for chloroquine (83). Since the architecture of the α – β interface is well conserved between the archaeobacterial and eukaryotic proteasomes, we may assume that the very similar allosteric routes constitute the molecular basis for functional effects of the drugs on the proteasome (83, 114, 126). As in the case of PR peptides described earlier, the presence of additional allosteric routes besides the established interface-antechamber link should be taken into account, especially that a part of NMR studies was performed without the presence of the β ring. For example, binding of the drugs may destabilize the α – β ring interactions and propagate allosteric signals directly to the catalytic chamber. Speculations about the molecular mechanism aside, the functional effects of 5AHQ are worth attention. *In vitro*, 5AHQ noncompetitively inhibits eukaryotic proteasome ChT-L and PGPH activities in micromolar concentrations, and displays synergistic effects when combined with bortezomib (83). 5AHQ is cytotoxic for established blood cancer cell lines, for primary myeloma and leukemia cells, and, importantly, also suppresses tumor growth in the mouse model of leukemia (83). The drug synergizes with bortezomib not only *in vitro* but also in cell culture, which is a phenomenon of unknown molecular mechanisms (83). Moreover, 5AHQ is cytotoxic to myeloma and non-small cell lung cancer cells, which displayed intrinsic or acquired resistance to bortezomib due to mutations in the β 5 inhibitor-binding pocket (24, 83). Obviously, the phenomenon of overcoming resistance to established drugs is of considerable interest for the prospective use of noncompetitive proteasome inhibitors in clinics. The intracellular specificity of 5AHQ remains to be established, and most likely, the proteasome will not be the sole target of this compound. However, both the affinity and the specificity of 5AHQ toward the proteasome are much better than in the case of chloroquine. Clearly, the anti-cancer preclinical effects of 5AHQ noted so far are very promising.

Concluding Remarks

Perhaps it is not surprising for such a giant enzyme complex with so many active sites and protein-binding

FIG. 6. Targeting the “ α/β interface to the antechamber” allosteric route. (A) A section through the side-view model of 20S proteasome structure, with the example of an interface area between α and β subunits circled, and the antechamber outlined with a white dotted line. (B) Structures of allosteric ligands of the core proteasome that utilize the α/β interface for binding: chloroquine [N⁴-(7-chloroquinolin-4-yl)-N¹,N¹-diethylpentane-1,4 diamine] and 5AHQ (83, 126). 5AHQ, 5-amino-8-hydroxyquinoline.

domains that there are so many types of small-molecule compounds which are known to affect its catalytic performance. Here, we described only those compounds that have been well studied, with reasonable well-delineated molecular mechanisms of action. We restricted this discussion to the catalytic core 20S particle, central for all assemblies and obligatory for the complex to bear the “proteasome” name. The described regulators engaging allosteric routes are likely to constitute a tip of the iceberg of potentially useful compounds, and are considered highly desirable due to the great diversity of their functional effects. There are two major approaches to search for more allosteric regulators. First, the already-identified allosteric routes can be targeted in rational drug design. The designer compounds may be destined to target any point within the allosteric path. The most straightforward and likely successful approach would be the targeting of the known receptor site. However, disrupting signaling between the receptor and effector sites may have the advantage of the lowest evolutionary pressure for drug-binding spots and a greater level of diversity of functional effects. Second, a broad high-throughput screening, virtual or with a library of compounds using a carefully targeted readout should fish out a variety of proteasome regulators. Some of the regulators may affect yet-unknown allosteric routes. The lead compounds may not necessarily be proteasome specific; however, they can be further optimized for improved *in vivo* performance. The critical issue in both the approaches is the application of an appropriate *in vitro* readout. Testing the workhorse ChT-L peptidase activity with a fluorogenic model peptide substrate, so popular in screens for competitive inhibitors, is not sufficient here. Allosteric ligands may perform poorly with the single-peptidase test yet display desirable *in vivo* effects, including interactions with regulatory modules, substrate specific inhibition or activation, or changes in a product's pattern. Using an array of model substrates and selected protein substrates should help pinpoint shifts in specificity. Fluorescent probes that are sensitive to structural changes in drug-treated proteasome particles would also come handy. Summarizing, searching for, and characterizing allosteric regulators of the proteasome are not trivial tasks. However, allosteric drugs may provide a truly comprehensive targeting of the UPP in general and the proteasome in particular, which is beneficial for the treatment of a variety of clinically relevant conditions.

Acknowledgments

M.G. and P.A.O. are grateful to the William and Ella Owens Foundation for Medical Research; to the Mike Hogg Foundation and Institute for Integration of Medicine and Science for their support. They thank Dr. Rochelle Buffenstein for a critical reading of this article and invaluable expert advice.

References

- Adams J. The proteasome: a suitable antineoplastic target. *Nat Rev Cancer* 4: 349–360, 2004.
- Adams J, Behnke M, Chen S, Cruickshank AA, Dick LR, Grenier L, Klunder JM, Ma YT, Plamondon L, and Stein RL. Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. *Bioorg Med Chem Lett* 8: 333–338, 1998.
- Apcher GS, Heink S, Zantopf D, Kloetzel PM, Schmid HP, Mayer RJ, and Kruger E. Human immunodeficiency virus-1 Tat protein interacts with distinct proteasomal alpha and beta subunits. *FEBS Lett* 553: 200–204, 2003.
- Arastu-Kapur S, Anderl JL, Kraus M, Parlati F, Shenk KD, Lee SJ, Muchamuel T, Bennett MK, Driessen C, Ball AJ, and Kirk CJ. Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events. *Clin Cancer Res* 17: 2734–2743, 2011.
- Arendt CS and Hochstrasser M. Identification of the yeast 20S proteasome catalytic centers and subunit interactions required for active-site formation. *Proc Natl Acad Sci U S A* 94: 7156–7161, 1997.
- Babbitt SE, Kiss A, Deffenbaugh AE, Chang YH, Bailly E, Erdjument-Bromage H, Tempst P, Buranda T, Sklar LA, Baumler J, Gogol E, and Skowyra D. ATP hydrolysis-dependent disassembly of the 26S proteasome is part of the catalytic cycle. *Cell* 121: 553–565, 2005.
- Bader M, Benjamin S, Wapinski OL, Smith DM, Goldberg AL, and Steller H. A conserved F box regulatory complex controls proteasome activity in *Drosophila*. *Cell* 145: 371–382, 2011.
- Banaszynski LA, Liu CW, and Wandless TJ. Characterization of the FKBP-rapamycin-FRB ternary complex. *J Am Chem Soc* 127: 4715, 2005.
- Bar-Nun S and Glickman MH. Proteasomal AAA-AT-Pases: structure and function. *Biochim Biophys Acta* 1823: 67–82, 2012.
- Bayer P, Kraft M, Ejchart A, Westendorp M, Frank R, and Rösch P. Structural studies of HIV-1 Tat protein. *J Mol Biol* 247: 529–535, 1995.
- Bochtler M, Ditzel L, Groll M, Hartmann C, and Huber R. The proteasome. *Ann Rev Biophys Biomol Struct* 28: 295–317, 1999.
- Bogyo M, McMaster JS, Gaczynska M, Tortorella D, Goldberg AL, and Ploegh H. Covalent modification of the active site threonine of proteasomal β subunits and the *Escherichia coli* homolog HsIV by a new class of inhibitors. *Proc Natl Acad Sci U S A* 94: 6629–6634, 1997.
- Bogyo M, Shin S, McMaster JS, and Ploegh HL. Substrate binding and sequence preference of the proteasome revealed by active-site-directed affinity probes. *Chem Biol* 5: 307–320, 1998.
- Borissenko L and Groll M. 20S proteasome and its inhibitors: crystallographic knowledge for drug development. *Chem Rev* 107: 687–717, 2007.
- Braun HA, Umbreen S, Groll M, Kuckelkorn U, Mlynarczuk I, Wigand ME, Drung I, Kloetzel P-M, and Schmidt B. Tripeptide mimetics inhibit the 20S proteasome by covalent bonding to the active threonines. *J Biol Chem* 280: 28394–28401, 2005.
- Chauhan D, Hideshima T, and Anderson KC. A novel proteasome inhibitor NPI-0052 as an anticancer therapy. *Br J Cancer* 95: 961–965, 2006.
- Chauhan D, Singh A, Brahmandam M, Podar K, Hideshima T, Richardson P, Munshi N, Palladino MA, and Andersone KC. Combination of proteasome inhibitors bortezomib and NPI-0052 trigger *in vivo* synergistic cytotoxicity in multiple myeloma. *Blood* 111: 1654–1664, 2008.
- Cho-Park PF and Steller H. Proteasome regulation by ADP-ribosylation. *Cell* 153: 614–627, 2013.
- Choi K-Y, Chow LNY, and Mookherjee N. Cationic host defence peptides: multifaceted role in immune modulation and inflammation. *J Inn Immunol* 4: 361–370, 2012.

20. Chu-Ping M, Slaughter CA, and DeMartino GN. Purification and characterization of a protein inhibitor of the 20S proteasome (macropain). *Biochim Biophys Acta* 1119: 303–311, 1992.
21. Ciechanover A. Intracellular protein degradation: from a vague idea thru the lysosome and the ubiquitin-proteasome system and onto human diseases and drug targeting. *Biochim Biophys Acta Proteins Proteomics* 1824: 3–13, 2012.
22. Cliff MJ, Kad NM, Hay N, Lund PA, Webb MR, Burston SG, and Clarke AR. A kinetic analysis of the nucleotide-induced allosteric transitions of GroEL. *J Mol Biol* 293: 667–684, 1999.
23. Crosas B, Hanna J, Kirkpatrick DS, Zhang DP, Tone Y, Hathaway N, Buecker C, Leggett DS, Schmidt M, King RW, Gygi S, and Finley D. Ubiquitin chains are remodeled at the proteasome by opposing ubiquitin ligase and deubiquitinating activities. *Cell* 127: 1401–1413, 2006.
24. De Wilt LHAM, Jansen G, Assaraf YG, Van Meerloo J, Cloos J, Schimmer AD, Chan ET, Kirk CJ, Peters GJ, and Kruyt FAE. Proteasome-based mechanisms of intrinsic and acquired bortezomib resistance in non-small cell lung cancer. *Biochem Pharmacol* 83: 207–217, 2012.
25. del Sol A, Tsai C-J, Ma B, and Nussinov R. The origin of allosteric functional modulation: multiple pre-existing pathways. *Structure* 17: 1042–1050, 2009.
26. Demo SD, Kirk CJ, Aujay MA, Buchholz TJ, Dajee M, Ho MN, Jiang J, Laidig GJ, Lewis ER, Parlato F, Shenk KD, Smyth MS, Sun CM, Vallone MK, Woo TM, Molineaux CJ, and Bennett MK. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. *Cancer Res* 67: 6383–6391, 2007.
27. Dick TP, Nussbaum AK, Deeg M, Heinemeyer W, Groll M, Schirle M, Keilholz W, Stevanovic S, Wolf DH, Huber R, Rammensee HG, and Schild H. Contribution of proteasomal beta-subunits to the cleavage of peptide substrates analyzed with yeast mutants. *J Biol Chem* 273: 25637–25646, 1998.
28. Elsasser S and Finley D. Delivery of ubiquitinated substrates to protein-unfolding machines. *Nat Cell Biol* 7: 742–749, 2005.
29. Fenteany G, Standaert RF, Lane WS, Choi S, Corey EJ, and Schreiber SL. Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. *Science* 268: 726–731, 1995.
30. Da Fonseca P, He J, and Morris EP. Molecular model of the human 26S proteasome. *Mol Cell* 46: 54–66, 2012.
31. Da Fonseca PCA and Morris EP. Structure of the human 26S proteasome: subunit radial displacements open the gate into the proteolytic core. *J Biol Chem* 283: 23305–23314, 2008.
32. Forster A, Masters EI, Whitby FG, Robinson H, and Hill CP. The 1.9 Å structure of a proteasome-11S activator complex and implications for proteasome-PAN/PA700 interactions. *Mol Cell* 18: 589–599, 2005.
33. Fostier K, De Becker A, and Schots R. Carfilzomib: a novel treatment in relapsed and refractory multiple myeloma. *Oncotarget Therapy* 5: 237–244, 2012.
34. Fotiadis D, Scheuring S, Muller SA, Engel A, and Muller DJ. Imaging and manipulation of biological structures with the AFM. *Micron* 33: 385–397, 2002.
35. Franke NE, Niewerth D, Assaraf YG, Van Meerloo J, Vojtekova K, Van Zantwijk CH, Zweegman S, Chan ET, Kirk CJ, Geerke DP, Schimmer AD, Kaspers GJL, Jansen G, and Cloos J. Impaired bortezomib binding to mutant $\beta 5$ subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells. *Leukemia* 26: 757–768, 2012.
36. Fu H, Reis N, Lee Y, Glickman MH, and Vierstra RD. Subunit interaction maps for the regulatory particle of the 26S proteasome and the COP9 signalosome. *EMBO J* 20: 7096–7107, 2001.
37. Gaczynska M, Osmulski PA, Gao Y, Post MJ, and Simons M. Proline- and arginine-rich peptides constitute a novel class of allosteric inhibitors of proteasome activity. *Biochemistry* 42: 8663–8670, 2003.
38. Gaczynska M and Osmulski PA. AFM of biological complexes: what can we learn?. *Curr Opin Colloid Interface Sci* 13: 351–367, 2008.
39. Gaczynska M and Osmulski PA. Atomic force microscopy of proteasome assemblies. *Methods Mol Biol* 736: 117–132, 2011.
40. Gaczynska M, Rock KL, and Goldberg AL. γ -Interferon and expression of MHC genes regulate peptide hydrolysis by proteasomes. *Nature* 365: 264–267, 1993.
41. Gao Y, Lecker S, Post MJ, Hietaranta AJ, Li J, Volk R, Li M, Sato K, Saluja AK, Steer ML, Goldberg AL, and Simons M. Inhibition of ubiquitin-proteasome pathway-mediated I κ B α degradation by a naturally occurring antibacterial peptide. *J Clin Invest* 106: 439–448, 2000.
42. Gavioli R, Gallerani E, Fortini C, Fabris M, Bottoni A, Canella A, Bonaccorsi A, Marastoni M, Micheletti F, Cafaro A, Rimessi P, Caputo A, and Ensoli B. HIV-1 Tat protein modulates the generation of cytotoxic T cell epitopes by modifying proteasome composition and enzymatic activity. *J Immunol* 173: 3838–3843, 2004.
43. Gillette TG, Kumar B, Thompson D, Slaughter CA, and DeMartino GN. Differential roles of the COOH termini of AAA subunits of PA700 (19S regulator) in asymmetric assembly and activation of the 26S proteasome. *J Biol Chem* 283: 31813–31822, 2008.
44. Glickman MH and Raveh D. Proteasome plasticity. *FEBS Lett* 579: 3214–3223, 2005.
45. Glickman MH, Rubin DM, Fu HY, Larsen CN, Coux O, Wefes I, Pfeifer G, Cjeka Z, Vierstra R, Baumeister W, Fried V, and Finley D. Functional analysis of the proteasome regulatory particle. *Mol Biol Rep* 26: 21–28, 1999.
46. Goodey NM and Benkovic SJ. Allosteric regulation and catalysis emerge via a common route. *Nat Chem Biol* 4: 474–482, 2008.
47. Groettrup M, Soza A, Eggers M, Kuehn L, Dick TP, Schild H, Rammensee HG, Koszinowski UH, and Kloetzel PM. A role for the proteasome regulator PA28 α in antigen presentation. *Nature* 381: 166–168, 1996.
48. Groll M, Bajorek M, Kohler A, Moroder L, Rubin DM, Huber R, Glickman MH, and Finley D. A gated channel into the proteasome core particle. *Nat Struct Biol* 7: 1062–1067, 2000.
49. Groll M, Bochtler M, Brandstetter H, Clausen T, and Huber R. Molecular machines for protein degradation. *ChemBioChem* 6: 222–256, 2005.
50. Groll M, Ditzel L, Lowe J, Stock D, Bochtler M, Bartunik HD, and Huber R. Structure of 20S proteasome from yeast at 2.4 Å resolution. *Nature* 386: 463–471, 1997.
51. Groll M, Kim KB, Kairies N, Huber R, and Crews CM. Crystal structure of epoxomicin: 20S proteasome reveals a molecular basis for selectivity of α , β -epoxyketone proteasome inhibitors. *J Am Chem Soc* 122: 1237–1238, 2000.
52. Groll M, Koguchi Y, Huber R, and Kohno J. Crystal structure of the 20S proteasome: TMC-95A complex: a non-covalent proteasome inhibitor. *J Mol Biol* 311: 543–548, 2001.

53. Groll M, Nazif T, Huber R, and Bogyo M. Probing structural determinants distal to the site of hydrolysis that control substrate specificity of the 20S proteasome. *Chem Biol* 9: 655–662, 2002.
54. Groll M, Schellenberg B, Bachmann AS, Archer CR, Huber R, Powell TK, Lindow S, Kaiser M, and Dudler R. A plant pathogen virulence factor inhibits the eukaryotic proteasome by a novel mechanism. *Nature* 452: 755–759, 2008.
55. Grolleau A, Bowman J, Puravs E, Hanash S, Garcia-sanz JA, and Beretta L. Global and specific translational control by rapamycin in T cells uncovered by microarrays and proteomics. *J Biol Chem* 277: 22175–22184, 2002.
56. Gunasekaran K, Ma B, and Nussinov R. Is allostery an intrinsic property of all dynamic proteins? *Proteins* 57: 433–443, 2004.
57. Hanna J, Hathaway NA, Tone Y, Crosas B, Elsasser S, Kirkpatrick D, Leggett DS, Gygi SP, King RW, and Finley D. Deubiquitinating enzyme Ubp6 functions noncatalytically to delay proteasomal degradation. *Cell* 127: 99–111, 2006.
58. Harrison DE, Strong R, Sharp ZD, Nelson JF, Astle CM, Flurkey K, Nadon NL, Wilkinson JE, Frenkel K, Carter CS, Pahor M, Javors MA, Fernandez E, and Miller RA. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. *Nature* 460: 392–395, 2009.
59. Hendil KB, Khan S, and Tanaka K. Simultaneous binding of PA28 and PA700 activators to 20S proteasomes. *Biochem J* 332: 749–754, 1998.
60. Ho YK, Bargagna-Mohan P, Wehenkel M, Mohan R, and Kim K-B. LMP2-specific inhibitors: chemical genetic tools for proteasome biology. *Chem Biol* 14: 419–430, 2007.
61. Horwitz AA, Navon A, Groll M, Smith DM, Reis C, and Goldberg AL. ATP-induced structural transitions in PAN, the proteasome-regulatory ATPase complex in archaea. *J Biol Chem* 282: 22921–22929, 2007.
62. Huang X, Seifert U, Salzmann U, Henklein P, Preissner R, Henke W, Sijts AJ, Kloetzel P-M, and Dubiel W. The RTP site shared by the HIV-1 Tat protein and the 11S regulator subunit α is crucial for their effects on proteasome function including antigen processing. *J Mol Biol* 323: 771–782, 2002.
63. Huber EM, Basler M, Schwab R, Heinemeyer W, Kirk CJ, Groettrup M, and Groll M. Immuno- and constitutive proteasome crystal structures reveal differences in substrate and inhibitor specificity. *Cell* 148: 727–738, 2012.
64. Ismail M, Henklein P, Huang X, Braumann C, Ruckert RI, and Dubiel W. Identification of HIV-1 Tat peptides for future therapeutic angiogenesis. *Eur J Haematol* 77: 157–165, 2006.
65. Jankowska E, Gaczynska M, Osmulski P, Sikorska E, Rostankowski R, Madabhushi S, Tokmina-Lukaszewska M, and Kasprzykowski F. Potential allosteric modulators of the proteasome activity. *Biopolymers* 93: 481–495, 2010.
66. Jankowska E, Stoj J, Karpowicz P, Osmulski PA, and Gaczynska M. The proteasome in health and disease. *Curr Pharm Des* 19: 1010–1028, 2013.
67. Kessler BM, Tortorella D, Altun M, Kisselev AF, Fiebigler E, Hekking BG, Ploegh HL, and Overkleeft HS. Extended peptide-based inhibitors efficiently target the proteasome and reveal overlapping specificities of the catalytic L-subunits. *Chem Biol* 8: 913–929, 2001.
68. Khafagy E-S and Morishita M. Oral biodrug delivery using cell-penetrating peptide. *Adv Drug Deliv Rev* 64: 531–539, 2012.
69. Kirk R, Laman H, Knowles PP, Murray-Rust J, Lomonosov M, Meziane EK, and McDonald NQ. Structure of a conserved dimerization domain within the F-box protein Fbxo7 and the PI31 proteasome inhibitor. *J Biol Chem* 283: 22325–22335, 2008.
70. Kisselev AF, Garcia-Calvo M, Overkleeft HS, Peterson E, Pennington MW, Ploegh HL, Thornberry NA, and Goldberg AL. The caspase-like sites of proteasomes, their substrate specificity, new inhibitors and substrates, and allosteric interactions with the trypsin-like sites. *J Biol Chem* 278: 35869–35877, 2003.
71. Kisselev AF, Kaganovich D, and Goldberg AL. Binding of hydrophobic peptides to several non-catalytic sites promotes peptide hydrolysis by all active sites of 20S proteasomes—evidence for peptide-induced channel opening in the alpha-rings. *J Biol Chem* 277: 22260–22270, 2002.
72. Kleijnen MF, Roelofs J, Park S, Hathaway NA, Glickman M, King RW, and Finley D. Stability of the proteasome can be regulated allosterically through engagement of its proteolytic active sites. *Nat Struct Mol Biol* 14: 1180–1188, 2007.
73. Krahn D, Ottmann C, and Kaiser M. The chemistry and biology of syringolins, glidobactins and cepafungins (syrbactins). *Nat Prod Rep* 28: 1854–1867, 2011.
74. Kriegenburg F, Seeger M, Saeki Y, Tanaka K, Lauridsen AMB, Hartmann-Petersen R, and Hendil KB. Mammalian 26S proteasomes remain intact during protein degradation. *Cell* 135: 355–365, 2008.
75. Kroll M, Arenzana-Seisdedos F, Bachelier F, Thomas D, Friguet B, and Conconi M. The secondary fungal metabolite gliotoxin targets proteolytic activities of the proteasome. *Chem Biol* 6: 689–698, 1999.
76. Kuhn DJ, Orlowski RZ, and Bjorklund CC. Second generation proteasome inhibitors: carfilzomib and immunoproteasome-specific inhibitors (IPSi). *Curr Cancer Drug Targets* 11: 285–295, 2011.
77. Kumar B, Kim Y-C, and DeMartino GN. The C terminus of Rpt3, an ATPase subunit of PA700 (19S) regulatory complex, is essential for 26S proteasome assembly but not for activation. *J Biol Chem* 285: 39523–39535, 2010.
78. Kyung BK, Myung J, Sin N, and Crews CM. Proteasome inhibition by the natural products epoxomicin and dihydroeponepin: insights into specificity and potency. *Bioorg Med Chem Lett* 9: 3335–3340, 1999.
79. Lander GC, Estrin E, Matyskiela ME, Bashore C, Nogales E, and Martin A. Complete subunit architecture of the proteasome regulatory particle. *Nature* 482: 186–191, 2012.
80. Lasker K, Förster F, Bohn S, Walzthoeni T, Villa E, Unverdorben P, Beck F, Aebbersold R, Sali A, and Baumeister W. Molecular architecture of the 26S proteasome holocomplex determined by an integrative approach. *Proc Natl Acad Sci U S A* 109: 1380–1387, 2012.
81. Li J, Gao X, Joss L, and Rechsteiner M. The proteasome activator 11S REG or PA28: chimeras implicate carboxyl-terminal sequences in oligomerization and proteasome binding but not in the activation of specific proteasome catalytic subunits. *J Mol Biol* 299: 641–654, 2000.
82. Li J, Post M, Volk R, Gao Y, Li M, Metais C, Sato K, Tsai J, Aird W, Rosenberg RD, Hampton TG, Li J, Sellke F, Carmeliet P, and Simons M. PR39, a peptide regulator of angiogenesis. *Nat Med* 6: 49–55, 2000.
83. Li X, Wood TE, Sprangers R, Jansen G, Franke NE, Mao X, Wang X, Zhang Y, Verbrugge SE, Adomat H, Li ZH, Trudel S, Chen C, Religa TL, Jamal N, Messner H, Cloos J, Rose DR, Navon A, Guns E, Batey RA, Kay LE, and Schimmer AD. Effect of noncompetitive proteasome in-

- hibition on bortezomib resistance. *J Natl Cancer Inst* 102: 1069–1082, 2010.
84. Liu CW, Corboy MJ, DeMartino GN, and Thomas PJ. Endoproteolytic activity of the proteasome. *Science* 299: 408–411, 2003.
 85. Lowe J, Stock D, Jap B, Zwickl P, Baumeister W, and Huber R. Crystal structure of the 20S proteasome from the archaeon *T. acidophilum* at 3.4 Å resolution. *Science* 268: 533–539, 1995.
 86. Matyskiela ME, Lander GC, and Martin A. Conformational switching of the 26S proteasome enables substrate degradation. *Nat Struct Mol Biol* 20: 781–788, 2013.
 87. McCutchen-Maloney SL, Matsuda K, Shimbara N, Binns DD, Tanaka K, Slaughter CA, and DeMartino GN. cDNA cloning, expression, and functional characterization of PI31, a proline-rich inhibitor of the proteasome. *J Biol Chem* 275: 18557–18565, 2000.
 88. Medalia N, Beer A, Zwickl P, Mihalache O, Beck M, Medalia O, and Navon A. Architecture and molecular mechanism of PAN, the archaeal proteasome regulatory ATPase. *J Biol Chem* 284: 22952–22960, 2009.
 89. Monod J, Wyman J, and Changeux JP. On the nature of allosteric transitions: a plausible model. *J Mol Biol* 12: 88–118, 1965.
 90. Murray SS, Tu KN, Young KL, and Murray EJB. The effects of lovastatin on proteasome activities in highly purified rabbit 20S proteasome preparations and mouse MC3T3-E1 osteoblastic cells. *Metabolism* 51: 1153–1160, 2002.
 91. Myung J, Kim KB, Lindsten K, Dantuma NP, and Crews CM. Lack of proteasome active site allostery as revealed by subunit-specific inhibitors. *Mol Cell* 7: 411–420, 2001.
 92. Nam S, Smith DM, and Dou QP. Ester bond-containing tea polyphenols potently inhibit proteasome activity *in vitro* and *in vivo*. *J Biol Chem* 276: 13322–13330, 2001.
 93. Nazif T and Bogoy M. Global analysis of proteasomal substrate specificity using positional-scanning libraries of covalent inhibitors. *Proc Natl Acad Sci U S A* 98: 2967–2972, 2001.
 94. Nussbaum AK, Dick TP, Keilholz W, Schirle M, Stevanovic S, Dietz K, Heinemeyer W, Groll M, Wolf DH, Huber R, Rammensee HG, and Schild H. Cleavage motifs of the yeast 20S proteasome beta subunits deduced from digests of enolase 1. *Proc Natl Acad Sci U S A* 95: 12504–12509, 1998.
 95. Nussinov R and Tsai C-J. Allostery in disease and in drug discovery. *Cell* 153: 293–305, 2013.
 96. Okada K, Wangpoengtrakul C, Osawa T, Toyokuni S, Tanaka K, and Uchida K. 4-Hydroxy-2-nonenal-mediated impairment of intracellular proteolysis during oxidative stress. Identification of proteasomes as target molecules. *J Biol Chem* 274: 23787–23793, 1999.
 97. Orlowski M, Cardozo C, and Michaud C. Evidence for the presence of five distinct proteolytic components in the pituitary multicatalytic proteinase complex. Properties of two components cleaving bonds on the carboxyl side of branched chain and small neutral amino acids. *Biochemistry* 32: 1563–1572, 1993.
 98. Orlowski M and Michaud C. Pituitary multicatalytic proteinase complex. Specificity of components and aspects of proteolytic activity. *Biochemistry* 28: 9270–9278, 1989.
 99. Osmulski PA and Gaczynska M. Atomic force microscopy reveals two conformations of the 20S proteasome from fission yeast. *J Biol Chem* 275: 13171–13174, 2000.
 100. Osmulski PA and Gaczynska M. Nanoenzymology of the 20S proteasome: proteasomal actions are controlled by the allosteric transition. *Biochemistry* 41: 7047–7053, 2002.
 101. Osmulski PA and Gaczynska M. Atomic force microscopy of the proteasome. In: *Ubiquitin and Protein Degradation, Part A*, edited by Deshaies RJ. Amsterdam: Elsevier, 2005, pp. 414–425.
 102. Osmulski PA and Gaczynska M. Rapamycin allosterically inhibits the proteasome. *Mol Pharmacol* 84: 104–113, 2013.
 103. Osmulski PA, Hochstrasser M, and Gaczynska M. A tetrahedral transition state at the active sites of the 20S proteasome is coupled to opening of the α -ring channel. *Structure* 17: 1137–1147, 2009.
 104. Pagano M, Tam SW, Theodoras AM, Beer-Romero P, Del Sal G, Chau V, Yew PR, Draetta GF, and Rolfe M. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. *Science* 269: 682–685, 1995.
 105. Palombella VJ, Rando OJ, Goldberg AL, and Maniatis T. The ubiquitin-proteasome pathway is required for processing the NF- κ B1 precursor protein and the activation of NF- κ B. *Cell* 78: 773–785, 1994.
 106. Parlati F, Lee SJ, Aujay M, Suzuki E, Levitsky K, Lorens JB, Micklem DR, Ruurs P, Sylvain C, Lu Y, Shenk KD, and Bennett MK. Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome. *Blood* 114: 3439–3447, 2009.
 107. Pickering AM and Davies KJA. Differential roles of proteasome and immunoproteasome regulators Pa28 α , Pa28 γ and Pa200 in the degradation of oxidized proteins. *Arch Biochem Biophys* 523: 181–190, 2012.
 108. Post MJ, Sato K, Murakami M, Bao J, Tirziu D, Pearlman JD, and Simons M. Adenoviral PR39 improves blood flow and myocardial function in a pig model of chronic myocardial ischemia by enhancing collateral formation. *Am J Physiol Regul Integr Comp Physiol* 290: R494–R500, 2006.
 109. Realini C, Jensen CC, Zhang Z, Johnston SC, Knowlton JR, Hill CP, and Rechsteiner M. Characterization of recombinant REGalpha, REGbeta, and REGgamma proteasome activators. *J Biol Chem* 272: 25483–25492, 1997.
 110. Rechsteiner M and Hill CP. Mobilizing the proteolytic machine: cell biological roles of proteasome activators and inhibitors. *Trends Cell Biol* 15: 27–33, 2005.
 111. Religa TL, Sprangers R, and Kay LE. Dynamic regulation of archaeal proteasome gate opening as studied by trosy NMR. *Science* 328: 98–102, 2010.
 112. Rock KL, Gramm C, Rothstein L, Clark K, Stein R, Dick L, Hwang D, and Goldberg AL. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. *Cell* 78: 761–771, 1994.
 113. Rock KL, York IA, Saric T, and Goldberg AL. Protein degradation and the generation of MHC class I-presented peptides. *Adv Immunol* 80: 1–70, 2002.
 114. Ruschak AM and Kay LE. Proteasome allostery as a population shift between interchanging conformers. *Proc Natl Acad Sci U S A* 109: E3454–E3462, 2012.
 115. Sadre-Bazzaz K, Whitby FG, Robinson H, Formosa T, and Hill CP. Structure of a Bln10 complex reveals common mechanisms for proteasome binding and gate opening. *Mol Cell* 37: 728–735, 2010.
 116. Saibil HR, Fenton WA, Clare DK, and Horwich AL. Structure and allostery of the chaperonin GroEL. *J Mol Biol* 425: 1476–1487, 2013.

117. Sanchez E, Li M, Steinberg JA, Wang C, Shen J, Bonavida B, Li Z-W, Chen H, and Berenson JR. The proteasome inhibitor CEP-18770 enhances the anti-myeloma activity of bortezomib and melphalan. *Br J Haematol* 148: 569–581, 2010.
118. Schmidt M, Haas W, Crosas B, Santamaria PG, Gygi SP, Walz T, and Finley D. The HEAT repeat protein Bln10 regulates the yeast proteasome by capping the core particle. *Nat Struct Mol Biol* 12: 294–303, 2005.
119. Schmidtke G, Emch S, Groettrup M, and Holzhütter H-G. Evidence for the existence of a non-catalytic modifier site of peptide hydrolysis by the 20S proteasome. *J Biol Chem* 275: 22056–22063, 2000.
120. Seeger M, Ferrell K, Frank R, and Dubiel W. HIV-1 Tat inhibits the 20S proteasome and its 11S regulator-mediated activation. *J Biol Chem* 272: 8145–8148, 1997.
121. Seemuller E, Lupas A, Stock D, Lowe J, Huber R, and Baumeister W. Proteasome from *Thermoplasma acidophilum*: a threonine protease. *Science* 268: 579–582, 1995.
122. Sinha N and Nussinov R. Point mutations and sequence variability in proteins: redistributions of preexisting populations. *Proc Natl Acad Sci U S A* 98: 3139–3144, 2001.
123. Smith DM, Chang SC, Park S, Finley D, Cheng Y, and Goldberg AL. Docking of the proteasomal ATPases' carboxyl termini in the 20S proteasome's $\square$? Ring opens the gate for substrate entry. *Mol Cell* 27: 731–744, 2007.
124. Smith DM, Kafri G, Cheng Y, Ng D, Walz T, and Goldberg AL. ATP binding to PAN or the 26S ATPases causes association with the 20S proteasome, gate opening, and translocation of unfolded proteins. *Mol Cell* 20: 687–698, 2005.
125. Sprangers R and Kay LE. Quantitative dynamics and binding studies of the 20S proteasome by NMR. *Nature* 445: 618–622, 2007.
126. Sprangers R, Li X, Mao X, Rubinstein JL, Schimmer AD, and Kay LE. TROSY-based NMR evidence for a novel class of 20S proteasome inhibitors. *Biochemistry* 47: 6727–6734, 2008.
127. Strickland D, Moffat K, and Sosnick TR. Light-activated DNA binding in a designed allosteric protein. *Proc Natl Acad Sci U S A* 105: 10709–10714, 2008.
128. Suzuki E, Demo S, Deu E, Keats J, Arastu-Kapur S, Bergsagel PL, Bennett MK, and Kirk CJ. Molecular mechanisms of bortezomib resistant adenocarcinoma cells. *PLoS One* 6:e277996, 2011.
129. Takahama Y, Takada K, Murata S, and Tanaka K. β 5t-containing thymoproteasome: specific expression in thymic cortical epithelial cells and role in positive selection of CD8⁺ T cells. *Curr Opin Immunol* 24: 92–98, 2012.
130. Unno M, Mizushima T, Morimoto Y, Tomisugi Y, Tanaka K, Yasuoka N, and Tsukihara T. The structure of the mammalian 20S proteasome at 2.75 Å resolution. *Structure* 10: 609–618, 2002.
131. Ustrell V, Hoffman L, Pratt G, and Rechsteiner M. PA200, a nuclear proteasome activator involved in DNA repair. *EMBO J* 21: 3516–3525, 2002.
132. Van Der Linden WA, Willems LI, Shabaneh TB, Li N, Ruben M, Florea BI, Van Der Marel GA, Kaiser M, Kisselev AF, and Overkleeft HS. Discovery of a potent and highly β 1 specific proteasome inhibitor from a focused library of urea-containing peptide vinyl sulfones and peptide epoxyketones. *Org Biomol Chem* 10: 181–194, 2012.
133. Vignot S. mTOR-targeted therapy of cancer with rapamycin derivatives. *Ann Oncol* 16: 525–537, 2005.
134. Whitby FG, Masters EL, Kramer L, Knowlton JR, Yao Y, Wang CC, and Hill CP. Structural basis for the activation of 20S proteasomes by 11S regulators. *Nature* 408: 115–120, 2000.
135. Wilk S and Orlowski M. Cation-sensitive neutral endopeptidase: isolation and specificity of the bovine pituitary enzyme. *J Neurochem* 35: 1172–1182, 1980.
136. Yifrach O and Horovitz A. Nested cooperativity in the ATPase activity of the oligomeric chaperonin GroEL. *Biochemistry* 34: 5303–5308, 1995.
137. Zaiss DM, Standera S, Holzhütter H, Kloetzel P, and Sijts AJ. The proteasome inhibitor PI31 competes with PA28 for binding to 20S proteasomes. *FEBS Lett* 457: 333–338, 1999.

Address correspondence to:

Dr. Maria Gaczynska

Department of Molecular Medicine

Institute of Biotechnology

University of Texas Health Science Center at San Antonio

15355 Lambda Drive

San Antonio, TX 78245

E-mail: gaczynska@uthscsa.edu

Date of first submission to ARS Central, December 30, 2013;
date of acceptance, January 12, 2014.

Abbreviations Used

5AHQ = 5-amino-8-hydroxyquinoline

Ada = adamantanyl acetate

AFM = atomic force microscopy

Ahx = aminohexanoic acids

ChT-L = chymotrypsin-like peptidase activity

CP = core particle

cryoEM = cryo-electron microscopy

DMSO = dimethylsulfoxide

Hb = hydrophobic amino-acid residue

HIF = hypoxia-inducible factor

HIV = human immunodeficiency virus

HIV-1 Tat = human immune deficiency virus type

1 transactivator

HNE = 4-hydroxy-2-nonenal

I κ B = inhibitor of κ B

MCA = 7-amido-4-methylcoumarin

NF- κ B = nuclear factor kappa-light-chain-enhancer of
activated B cells

mTOR = mammalian target of rapamycin

NMR = nuclear magnetic resonance

PA = proteasome activator

PGPH = post-glutamyl peptide hydrolyzing activity

PR = Pro- and Arg-rich peptides

REG = regulator

RP = regulatory particle

Rpt = regulatory particle ATPases

RTP = REG/Tat-proteasome binding

S = Svedberg sedimentation unit

SPM = scanning probe microscopy

Suc = succinyl

Tat = transactivator

T-L = trypsin-like activity

UPP = ubiquitin-proteasome pathway

VS = vinyl sulfone